E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the superiority of sotagliflozin 400 mg versus placebo on Hemoglobin A1c (HbA1c) reduction at Week 26 in patients with type 2 diabetes (T2D) who have inadequate glycemic control with a sulfonylurea alone or in combination with metformin |
|
E.2.2 | Secondary objectives of the trial |
-To compare sotagliflozin 400 mg versus placebo based on:
-Change from baseline in fasting plasma glucose (FPG).
-Change from baseline in systolic blood pressure (SBP) for patients with baseline SBP ≥130 mm Hg.
-Change from baseline in SBP for all patients.
-Change from baseline in body weight.
-Proportion of patients with HbA1c <6.5% and <7.0%.
-To evaluate the safety of sotagliflozin 400 mg versus placebo throughout the 79 -week trial.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Patients with T2D treated with a sulfonylurea (≥half the maximum recommended dose as per local label or maximum tolerated dose [documented]) as monotherapy or in combination with metformin (≥1500 mg per day or maximum tolerated dose[documented]) each at a stable dose for at least 12 weeks without a dose adjustment before enrollment.
-Signed written informed consent. |
|
E.4 | Principal exclusion criteria |
-At the time of screening age <18 years.
-Hemoglobin A1c (HbA1c) <7% or HbA1c >10% via central lab test at screening.
-Fasting plasma glucose (FPG) >15 mmol/L (270 mg/dL) measured by the central laboratory at screening (Visit 1), and confirmed (>15 mmol/L [270 mg/dL]) by a repeat test before randomization.
-Women of childbearing potential with no effective contraceptive method.
-Treated with an antidiabetic pharmacological regimen other than a sulfonylurea at a stable dose with or without metformin within 12 weeks preceding the screening visit.
-Previous insulin use >1 month (at any time, aside from treatment of gestational diabetes).
-History of prior gastric surgical procedure including gastric banding or inflammatory bowel disease within 3 years before the Screening Visit.
-History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior to the Screening Visit.
-History of severe hypoglycemia within 6 months prior to the Screening visit.
-Systolic blood pressure (SBP) >180 mmHg or diastolic blood pressure (DBP) >100 mmHg or history of hypertensive emergency
-Aspartate aminotransferase and/or alanine aminotransferase: >3 times the upper limit of the normal laboratory range (ULN)
-Total bilirubin: >1.5 times ULN (except in case of Gilbert’s syndrome).
-Use of systemic glucocorticoids (excluding topical or ophthalmic, application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.
-Pregnancy, breastfeeding.
-Patient is unwilling to perform self-monitoring of blood glucose (SMBG), and complete the patient’s diary as required per protocol.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in HbA1c |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1- Change from baseline in FPG
2- Change from baseline in SBP for patients with baseline SBP ≥130 mmHg
3- Change from baseline in SBP for all patients
4- Change from baseline in body weight
5- Percentage of patients with HbA1c <6.5%
6- Percentage of patients with HbA1c <7.0%
7- Measurement of bone metabolism markers
8- Measurement of calcium metabolism markers
9- Measurement of intestinal transit markers
10- Measurement of intestinal absorption markers |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1- Change from baseline in FPG : Baseline to Week 26
2- Change from baseline in SBP for patients with baseline SBP ≥130 mmHg : Baseline to Week 12
3- Change from baseline in SBP for all patients : Baseline to Week 12
4- Change from baseline in body weight : Baseline to Week 26
5- Percentage of patients with HbA1c <6.5% : At Week 26
6- Percentage of patients with HbA1c <7.0% : At Week 26
7- Measurement of bone metabolism markers : Baseline to Week 79
8- Measurement of calcium metabolism markers : Baseline to Week 79
9- Measurement of intestinal transit markers : Baseline to Week 79
10- Measurement of intestinal absorption markers : Baseline to Week 79 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bulgaria |
Estonia |
Hungary |
Korea, Republic of |
Poland |
Romania |
Slovakia |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |